Enanta Pharmaceuticals

Enanta Pharmaceuticals is a United States-based company located in Watertown, Massachusetts. The company employs 169 individuals and generates $91.6 million in annual revenue. Enanta Pharmaceuticals focuses on the discovery and development of small molecule drugs for virology and immunology indications. Their research efforts are currently centered around respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The company has a history of advancing clinical-stage compounds for various viral infections, including SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV). Enanta Pharmaceuticals played a crucial role in the development of Glecaprevir, a protease inhibitor that is a component of leading treatment regimens for curing chronic hepatitis C virus (HCV) infection. Glecaprevir is marketed by AbbVie in numerous countries under the brand names MAVYRET® in the U.S. and MAVIRET® internationally. Enanta receives royalties from these HCV products, which contribute to the company's ongoing operations. For more information, visit www.enanta.com.